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Introduction
Osteoarthritis is estimated to affect 40 million people in the
United States and 70 to 90% of Americans over 75 years
of age1,2. Annual costs associated with arthritis (direct
medical expenses and lost wages) were estimated at
$95 billion in 2000, and this cost will increase as its
prevalence increases1. A number of pharmacologic inter-
ventions are used to manage osteoarthritis, including
acetaminophen, nonsteroidal anti-inflammatory drugs
(NSAIDs), or cyclooxygenase-2 (COX-2) inhibitors as
appropriate for mild-to-moderate pain; tramadol or opioid
combinations for moderately severe pain, and opioids for
severe pain2–4. Regardless of the pain severity, pharmaco-
logic monotherapy may not be sufficient, and individuals
with osteoarthritis pain often require combination therapy5.
The lidocaine patch 5%, a targeted peripheral analgesic,
has proven efficacy in the treatment of pain secondary to
postherpetic neuralgia6,7. It inhibits voltage-gated sodium
channels8, which may contribute to osteoarthritis pain sig-
naling. Here, we report findings of a pilot open-label trial
designed to assess effectiveness of the lidocaine patch 5%
in patients with osteoarthritis of one or both knees, who had
experienced an incomplete response to stable doses of
analgesic therapy and to determine if further randomized
controlled trials were warranted.
Methods
STUDY POPULATION
This 2-week, prospective, multicenter, open-label, non-
randomized pilot study was conducted in men and women
≥18 years of age with osteoarthritis of one or both knees,
who were using a stable analgesic regimen (e.g. aceta-
minophen, NSAIDs, COX-2 inhibitors, tramadol, opioids).
Patients provided informed written consent and were
eligible if they had typical knee osteoarthritis symptoms of
pain, stiffness, and disability that required scheduled treat-
ment with a stable dose analgesic. Patients were required
to have average daily pain intensity >4/10 (0=no pain
to 10=pain as bad as ever imagined), as measured by
Question 5 of the Brief Pain Inventory (BPI).
TREATMENT
Treatment consisted of once-daily (q24h) applications of
commercially available lidocaine patch 5% to the area(s) of
maximal knee pain. Investigators prescribed a maximum
of four patches (560 cm2) daily per patient; patients were
instructed to cover as much of the painful region as
possible and to reapply new patches at approximately the
same time each day. No dose adjustments or additions
other than the lidocaine patch 5% were allowed during the
study.
OUTCOME MEASURES
BPI scores were used to assess pain control: worst,
average, and least daily pain intensity; pain right now; and
percent pain relief. Additional outcome measures included
the Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis Index, and patient/investigator global assess-
ment of patch satisfaction. Quality of life (QOL) was
assessed by the seven domains of BPI Question 9: general
activity, mood, walking ability, normal work, relationships
with other people, sleep, and enjoyment of life. Safety was
assessed from adverse event (AE) reports, vital signs,
clinical laboratory tests, and physical examinations.
STATISTICAL METHODOLOGY
The primary efficacy end-point was mean change from
baseline to Week 2 in average daily pain intensity. Second-
ary efficacy analyses included mean changes from base-
line to Week 2 in other pain intensity, pain relief, and QOL
scores on the BPI, as well as WOMAC scores. Primary
and secondary end-points were analyzed using paired
Student’s t-tests; the global assessment of satisfaction with
patch therapy was analyzed using nonparametric methods.
All patients who received study medication were included
in safety analyses. A significance level of 0.05 was used for
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all statistical analyses, which were performed using SAS
version 6.12.
STUDY PARTICIPANTS
A total of 137 patients were enrolled at eight study sites.
Baseline demographics and patient characteristics are
summarized in Table I. Patients ranged in age from
35 years to 85 years (mean, 61.0 years). The majority of
patients were Caucasian (108 [79%]), and 95 (69%)
women and 42 (31%) men were enrolled. Mean duration of
oseteoarthritis prior to lidocaine patch 5% therapy was
approximately 9 years in either knee. On average, patients
applied 2.2±1.1 patches daily; the majority of patients (100
[73%]) used patches on only one knee.
Results
Average pain intensity scores were 29% lower after
2 weeks of lidocaine patch 5% treatment (4.2±2.2) com-
pared to baseline (5.9±1.5; P<0.001); similar improve-
ments were recorded for worst pain, least pain, average
pain, and pain relief. Sixty-six (49%) patients reported at
least 30% improvement in average pain intensity and 64
(48%) patients reported at least 30% improvement in worst
pain intensity.
Significant improvements were also observed for all
WOMAC subscale scores and the WOMAC composite
index (P<0.001). At least 50% improvement was reported
by 54 (40%), 53 (40%), 50 (38%), and 50 (38%) patients for
the WOMAC pain, stiffness, physical function, and com-
posite scores, respectively (Table II).
At Week 2, significant improvements were observed for
all BPI measures of pain interference with QOL due to
osteoarthritis. The BPI composite score for QOL impair-
ment decreased from 37.2±13.7 at baseline to 23.5±15.1 at
Week 2 (P<0.001), and 78 (58%) patients reported at least
30% improvement in this score. The majority of patients
(94/134 [70%]) and investigators (84/130 [65%]) were
satisfied or very satisfied with the lidocaine patch 5%
overall.
Fourteen (10%) patients experienced treatment-related
AEs. Mild-to-moderate treatment-related AEs reported by
more than one patient included headache (4), dermatitis
(3), and taste disturbance (2). Five (3.6%) patients discon-
tinued due to treatment-related AEs, including dermatitis
(2), headache, headache+increased blood pressure, and
increased knee pain; 2 patients (1.5%) discontinued due to
AEs unrelated to study medication. There were no serious
AEs reported during the trial. There were no statistically
significant or clinically significant changes from baseline to
Week 2 in vital signs (including heart rate), laboratory
values, or physical examinations.
Application site dermal assessments were performed at
each visit. At Week 2, a total of 308 application sites were
evaluated for erythema: no erythema was found at 290
(93.2%), and there were no cases of moderate or severe
erythema. Of the 311 sites assessed for edema, edema
was absent at 278 (89.4%), and it was recorded as mod-
erate or severe at 3 (0.9%) sites. Papules with very slight
erythema and slight edema were found at one patch
application site. Sensation to light touch was maintained
at application sites in 126 (96%) of 131 patients, and
sensation to pinprick was maintained in 126 (98%) of 129
patients.
Discussion
In this 2-week, prospective, multicenter, open-label pilot
study, addition of the lidocaine patch 5% to analgesic
therapy, such as acetaminophen, NSAIDs, COX-2 inhibi-
tors, and tramadol, significantly reduced pain intensity and
improved function in patients with osteoarthritis pain in one
or both knees. Approximately 40% of all patients experi-
enced at least a 50% improvement in WOMAC subitems for
pain, stiffness, physical function, and composite score, The
results also showed that treatment with the lidocaine patch
Table I
Patient Demographics and baseline characteristics
All Patients (N=137)
Age, y
Mean (S.D.) 61.0 (12.2)
Range 35–85
Race/ethnicity
Caucasian, N (%) 108 (79)
Hispanic or Latino, N (%) 14 (10)
African American, N (%) 11 (8)
Asian, N (%) 4 (3)
Sex
Male, N (%) 42 (31)
Female, N (%) 95 (69)
Osteoarthritis duration – left knee, y
N 126
Mean (S.D.) 8.7 (8.4)
Range 0–42
Osteoarthritis duration – right knee, y
N 122
Mean (S.D.) 9.4 (8.2)
Range 0–42
Table II
Western Ontario and McMaster Universities osteoarthritis index scores* at baseline and after two weeks of lidocaine patch 5% treatment
Baseline Week 2
N Mean (S.D.) N Mean (S.D.) P value
Pain 136 285.3 (81.0) 134 181.1 (113.3) <0.001
Stiffness 136 133.3 (38.4) 134 80.5 (53.2) <0.001
Physical function 135 952.1 (308.2) 134 634.3 (404.5) <0.001
Composite index 135 1371.0 (394.0) 134 895.9 (554.1) <0.001
*Greater scores represent more severe dysfunction.
254 F. Burch et al.: Lidocaine patch in osteoarthritis pain
5% significantly improved mean pain interference with QOL
scores, and 58% of patients reported clinically meaningful
(≥30%) improvement in the composite score of BPI
Question 9.
The lidocaine patch 5% was also safe and well tolerated
in this patient population. There were relatively few
treatment-related AEs (most of which were mild or moder-
ate in severity) and no serious AEs. Additionally, no
clinically significant changes in clinical laboratory values or
vital signs were observed. Dermal reactions at application
sites were rare. Although topical lidocaine in other formu-
lations is commonly used for its local anesthetic properties,
the vast majority of patients reported no loss of sensation to
light touch or pinprick after 2 weeks of lidocaine patch 5%
treatment, suggesting that daily application of the lidocaine
patch 5% provided analgesia without local anesthesia.
This trial is the first prospective clinical study to demon-
strate the effectiveness and safety of the lidocaine patch
5% in the treatment of osteoarthritis pain. However, the
efficacy and safety of the lidocaine patch 5% have been
demonstrated previously in prospective trials among
patients with postherpetic neuralgia6,7,9–11, and clinical
case reports have described the effectiveness of lidocaine
patch 5% in patients with other forms of neuropathic or
musculoskeletal pain12,13.
In conclusion, the lidocaine patch 5% appears to be
effective as an add-on therapy for osteoarthritis pain. The
use of up to four patches, changed q24h, provides effective
anagesia without anesthesia and reduces stiffness, dis-
ability, and QOL impairment in patients who have
responded incompletely to prior analgesic therapy. This
new therapy offers clinicians an effective topical analgesic
option for osteoarthritis with a minimal risk of systemic
toxicity or drug-drug interactions. Controlled clinical trials
are needed to confirm the efficacy and safety of lidocaine
patch 5% therapy in the large and growing patient
population with osteoarthritis.
Disclosure
Clinical sites participating in this trial received grants
for patient enrollment from Endo Pharmaceuticals, Inc.,
Chadds Ford, PA.
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